A retrospective study assessing efficacy and safety of nivolumab in French patients with non-small cell lung cancer
Latest Information Update: 28 Jul 2016
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 28 Jul 2016 New trial record
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology